Haldol

Haldol is an injectable solution containing the antipsychotic haloperidol. It is supplied in a strength for intramuscular administration and is marketed in the European Union as a prescription medication. Haloperidol belongs to the butyrophenone class and works primarily as a dopamine D2 receptor antagonist. It is prescribed when oral therapy is not feasible or rapid symptom control is needed. The drug is available only with a healthcare provider’s authorization.

Haloperidol injectable solution is indicated for several acute psychiatric conditions that require rapid control of symptoms.

- Schizophrenia, particularly acute exacerbations. - Acute psychosis associated with mood disorders. - Mania episodes in bipolar disorder. - Severe agitation or aggression requiring intramuscular therapy. - Tourette syndrome when oral agents are insufficient.

Side effects of haloperidol injection vary in frequency and severity.

Common: - Drowsiness or sedation. - Extrapyramidal symptoms such as tremor or rigidity. - Dry mouth and increased salivation. - Orthostatic hypotension or dizziness. - Blurred vision or other visual disturbances.

Serious: - Neuroleptic malignant syndrome, a life‑threatening reaction. - Tardive dyskinesia with persistent involuntary movements. - Severe cardiac arrhythmias, including QT prolongation. - Seizures or loss of consciousness.

When prescribing haloperidol injection, clinicians should consider several precautionary measures to minimize risk.

- Assess for a history of cardiovascular disease or arrhythmias. - Monitor for signs of extrapyramidal reactions, especially in young patients. - Use the lowest effective dose and limit duration of therapy. - Evaluate liver and kidney function before initiating treatment. - Caution in patients with a personal or family history of seizures. - Avoid use during pregnancy unless benefits outweigh risks (category unknown). - Review any history of neuroleptic malignant syndrome.

Haloperidol can interact with other medications, affecting its efficacy or safety profile.

Avoid: - Other dopamine antagonists or antipsychotics that may increase extrapyramidal risk. - Drugs that prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that raise haloperidol levels.

Use with caution: - CNS depressants, including benzodiazepines and opioids, which can enhance sedation. - Anticholinergic agents, which may mask early signs of extrapyramidal symptoms. - Alcohol, because it may increase drowsiness and hypotension.